Oppenheimer Research Analysts Cut Earnings Estimates for Aptose Biosciences Inc. (NASDAQ:APTO)

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) – Oppenheimer cut their FY2021 earnings per share (EPS) estimates for shares of Aptose Biosciences in a report issued on Wednesday, March 27th, according to Zacks Investment Research. Oppenheimer analyst M. Biegler now expects that the biotechnology company will post earnings of ($0.59) per share for the year, down from their previous estimate of ($0.54). Oppenheimer has a “Outperform” rating and a $6.00 price target on the stock. Oppenheimer also issued estimates for Aptose Biosciences’ FY2022 earnings at ($0.73) EPS.

A number of other research analysts also recently commented on the company. Zacks Investment Research downgraded Aptose Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, January 8th. HC Wainwright set a $9.00 price target on Aptose Biosciences and gave the company a “buy” rating in a research note on Friday, March 22nd. Citigroup started coverage on Aptose Biosciences in a research note on Friday, January 25th. They issued an “outperform” rating and a $6.00 price target for the company. Finally, Royal Bank of Canada started coverage on Aptose Biosciences in a research note on Friday, March 1st. They issued an “outperform” rating and a $6.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Aptose Biosciences presently has an average rating of “Buy” and an average target price of $5.71.

Shares of Aptose Biosciences stock traded down $0.03 during trading on Monday, reaching $1.88. The company’s stock had a trading volume of 58,678 shares, compared to its average volume of 266,904. The stock has a market cap of $76.88 million, a PE ratio of -2.17 and a beta of 1.61. Aptose Biosciences has a 52 week low of $1.57 and a 52 week high of $4.55.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last announced its earnings results on Tuesday, March 12th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.16) by ($0.01).

Institutional investors have recently added to or reduced their stakes in the company. Noven Financial Group Inc. acquired a new position in shares of Aptose Biosciences in the fourth quarter valued at approximately $27,000. Geode Capital Management LLC acquired a new position in shares of Aptose Biosciences in the fourth quarter valued at approximately $33,000. Boston Advisors LLC acquired a new position in shares of Aptose Biosciences in the first quarter valued at approximately $36,000. Citadel Advisors LLC acquired a new position in shares of Aptose Biosciences in the third quarter valued at approximately $125,000. Finally, Patriot Financial Group Insurance Agency LLC increased its stake in shares of Aptose Biosciences by 11.4% in the fourth quarter. Patriot Financial Group Insurance Agency LLC now owns 57,429 shares of the biotechnology company’s stock valued at $110,000 after buying an additional 5,890 shares during the period. 7.68% of the stock is owned by institutional investors.

In other Aptose Biosciences news, CFO Gregory K. Chow bought 15,000 shares of the stock in a transaction on Wednesday, March 13th. The stock was purchased at an average price of $1.75 per share, with a total value of $26,250.00. Following the completion of the purchase, the chief financial officer now owns 122,014 shares in the company, valued at $213,524.50. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Erich Platzer sold 20,000 shares of the business’s stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $2.19, for a total value of $43,800.00. The disclosure for this sale can be found here. In the last three months, insiders have acquired 35,000 shares of company stock valued at $63,750.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Further Reading: The risks of owning bonds

Get a free copy of the Zacks research report on Aptose Biosciences (APTO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aptose Biosciences (NASDAQ:APTO)

Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.